CLDX CELLDEX THERAPEUTICS INC NEW revenue, earnings and financials

For the quarter ended June 30, 2026, CELLDEX THERAPEUTICS INC NEW reported revenue of $22.0K (down 97.0% from a year earlier), net income of −$73.5M and diluted EPS of −$0.94; for the fiscal year ended December 2025 revenue was $1.55M, down 78.0% on the year before.

CLDX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.55M, gross profit n/a, operating income −$287M, net income −$259M (margin -16748.0%), EPS −$3.90
• Fiscal year ended Dec 2024: revenue $7.02M, gross profit n/a, operating income −$195M, net income −$158M (margin -2248.8%), EPS −$2.45
• Fiscal year ended Dec 2023: revenue $6.88M, gross profit n/a, operating income −$155M, net income −$141M (margin -2054.8%), EPS −$2.92
• Fiscal year ended Dec 2022: revenue $2.36M, gross profit n/a, operating income −$115M, net income −$112M (margin -4765.6%), EPS −$2.40
• Fiscal year ended Dec 2021: revenue $4.65M, gross profit n/a, operating income −$71.2M, net income −$70.5M (margin -1516.0%), EPS −$1.64

CLDX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $22.0K (down 97.0% year over year), net income −$73.5M, EPS −$0.94
• Quarter ended Mar 31, 2026: revenue $15.0K (down 97.8% year over year), net income −$78.7M, EPS −$1.18
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$81.3M, EPS −$1.23
• Quarter ended Sep 30, 2025: revenue n/a, net income −$67.0M, EPS −$1.01
• Quarter ended Jun 30, 2025: revenue $730K (down 70.8% year over year), net income −$56.6M, EPS −$0.85
• Quarter ended Mar 31, 2025: revenue $695K (up 345.5% year over year), net income −$53.8M, EPS −$0.81
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.18M (down 71.6% year over year), net income −$47.1M, EPS −$0.71
• Quarter ended Sep 30, 2024: revenue $3.19M (up 110.3% year over year), net income −$42.1M, EPS −$0.64
• Quarter ended Jun 30, 2024: revenue $2.50M (up 832.1% year over year), net income −$35.8M, EPS −$0.54
• Quarter ended Mar 31, 2024: revenue $156K (down 83.9% year over year), net income −$32.8M, EPS −$0.56
• Quarter ended Dec 31, 2023 (from the annual report): revenue $4.13M (up 156.1% year over year), net income n/a, EPS −$0.84
• Quarter ended Sep 30, 2023: revenue $1.52M (up 272.7% year over year), net income n/a, EPS −$0.81
• Quarter ended Jun 30, 2023: revenue $268K (up 64.4% year over year), net income n/a, EPS −$0.65
• Quarter ended Mar 31, 2023: revenue $967K (up 455.7% year over year), net income n/a, EPS −$0.62
• Quarter ended Dec 31, 2022 (from the annual report): revenue $1.61M (up 384.4% year over year), net income n/a, EPS −$0.57
• Quarter ended Sep 30, 2022: revenue $407K (up 166.0% year over year), net income n/a, EPS −$0.57
• Quarter ended Jun 30, 2022: revenue $163K (down 95.3% year over year), net income n/a, EPS −$0.77
• Quarter ended Mar 31, 2022: revenue $174K (down 74.6% year over year), net income n/a, EPS −$0.49
• Quarter ended Dec 31, 2021 (from the annual report): revenue $333K, net income n/a, EPS −$0.43
• Quarter ended Sep 30, 2021: revenue $153K, net income n/a, EPS −$0.45

CLDX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$211M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$158M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$107M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$104M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$60.9M, share buybacks n/a

CLDX balance sheet

• Jun 30, 2026: cash $47.5M, total assets $782M, total liabilities $67.8M, shareholders' equity $715M
• Mar 31, 2026: cash $35.7M, total assets $511M, total liabilities $55.0M, shareholders' equity $456M
• Dec 31, 2025: cash $28.9M, total assets $583M, total liabilities $55.8M, shareholders' equity $527M
• Sep 30, 2025: cash $36.0M, total assets $648M, total liabilities $50.1M, shareholders' equity $598M
• Jun 30, 2025: cash $23.0M, total assets $692M, total liabilities $37.0M, shareholders' equity $655M
• Mar 31, 2025: cash $17.1M, total assets $739M, total liabilities $36.5M, shareholders' equity $703M
• Dec 31, 2024: cash $28.4M, total assets $792M, total liabilities $45.3M, shareholders' equity $747M
• Sep 30, 2024: cash $36.4M, total assets $823M, total liabilities $37.3M, shareholders' equity $786M

What is CLDX's revenue?

CELLDEX THERAPEUTICS INC NEW reported $1.55M of revenue for the fiscal year ended December 2025.

Is CLDX profitable?

No. CELLDEX THERAPEUTICS INC NEW lost $301M over the last four quarters.

What is CLDX's EPS?

Diluted earnings per share over the last four quarters were −$4.36; −$0.94 in the latest quarter.

CLDX ownership and insider trades · All stocks